Share Prices & Company Research

Market News

09 Apr 2019 | 07:42

Nuformix forms cannabinoid therapeutics partnership with Ebers Tech

Nuformix said it had signed an agreement for cannabinoid therapeutics development with Canadian company Ebers Tech.

The agreement would enables Ebers to employ Nuformix's technology platforms to bring a range of therapeutic cannabinoid products to market for consumer product and pharmaceutical applications.

The deal contained up to £51m of upfront, R&D and milestone payments, plus long-term royalties of 20% of net sales, Nuformix said.

Nuformix said it would receive a 'significant' upfront payment and 'believes it will earn further R&D and early-stage milestone payments up to a total of £1m during 2019'.

Further pre-clinical and clinical milestone payments were expected in 2020 and 2021, in addition to royalty payments of 20%.

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.